Top Page
BioCardia
(NASDAQ:BCDA)
BioCardia (BCDA) vs. SPDR S&P 500 ETF (SPY)
BioCardia Business Overview & Revenue Model
BioCardia Earnings Call Summary
BioCardia Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 58.00K | 477.00K | 1.35M | 1.01M | 145.00K |
| Gross Profit | -4.42M | -4.33M | -7.25M | -7.48M | 375.00K | 141.00K |
| EBITDA | -8.44M | -7.93M | -11.56M | -11.82M | -12.57M | -14.44M |
| Net Income | -8.54M | -7.95M | -11.57M | -11.91M | -12.62M | -15.00M |
Balance Sheet | ||||||
| Total Assets | 6.15M | 3.72M | 2.99M | 9.79M | 15.72M | 23.42M |
| Cash, Cash Equivalents and Short-Term Investments | 5.29M | 2.37M | 1.10M | 7.36M | 12.87M | 21.41M |
| Total Debt | 638.00K | 951.00K | 1.31M | 1.63M | 1.87M | 614.00K |
| Total Liabilities | 3.52M | 2.89M | 4.59M | 4.90M | 5.34M | 4.25M |
| Stockholders Equity | 2.63M | 837.00K | -1.60M | 4.89M | 10.38M | 19.18M |
Cash Flow | ||||||
| Free Cash Flow | -7.51M | -8.03M | -9.99M | -10.63M | -10.48M | -12.39M |
| Operating Cash Flow | -7.51M | -8.03M | -9.97M | -10.56M | -10.37M | -12.36M |
| Investing Cash Flow | -2.00K | -6.00K | -12.00K | -70.00K | -116.00K | -32.00K |
| Financing Cash Flow | 7.87M | 9.30M | 3.73M | 5.12M | 1.95M | 28.21M |
BioCardia Technical Analysis
BioCardia Risk Analysis
BioCardia Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $11.94M | ― | ― | ― | ― | ― | |
48 Neutral | $11.81M | ― | -207.73% | ― | 1.70% | -111.67% | |
46 Neutral | $14.01M | -0.61 | -317.47% | ― | -100.00% | 58.50% | |
45 Neutral | $9.67M | -0.19 | -81.97% | ― | -46.88% | 34.83% | |
41 Neutral | $6.55M | -0.16 | -404.48% | ― | -59.21% | 68.97% |
BioCardia Corporate Events
BioCardia, Inc., based in Sunnyvale, California, is a biotechnology company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, utilizing its proprietary biotherapeutic delivery platforms.
On November 10, 2025, BioCardia announced the enrollment of the first patient at Henry Ford Health in its Phase 3 CardiAMP HF II clinical trial for ischemic heart failure with reduced ejection fraction. This trial aims to confirm the safety and efficacy of the CardiAMP autologous cell therapy, which previously showed promising results in reducing mortality and improving quality of life for patients. The trial’s success could address significant clinical needs for the approximately 2 million patients in the U.S. and EU suffering from this condition, potentially impacting patient care and the healthcare system.
The most recent analyst rating on (BCDA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
On October 30, 2025, BioCardia, Inc. announced that the University of Wisconsin School of Medicine and Public Health enrolled its first patient in the ongoing Phase 3 CardiAMP HF II clinical trial. This trial aims to confirm the safety and efficacy of CardiAMP autologous cell therapy for ischemic heart failure patients with reduced ejection fraction. The study, which involves 250 patients, utilizes a composite primary outcome measure and incorporates advancements in cell population analysis and delivery systems. The enrollment at this prestigious cardiology center is expected to strengthen the trial and potentially broaden the availability of this therapy.
The most recent analyst rating on (BCDA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
BioCardia’s CardiAMP Heart Failure II Trial is a pivotal study aimed at assessing the safety and efficacy of the CardiAMP cell therapy system in patients with ischemic heart failure. Officially titled ‘Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients With Ischemic Heart Failure II Trial,’ the study seeks to provide therapeutic benefits for those suffering from reduced ejection fraction due to ischemic heart failure.
BioCardia, Inc. is conducting a Phase I/II clinical trial titled ‘Phase I/II Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells (hMSCs) in Patients With Ischemic Heart Failure With Reduced Ejection Fraction (HFrEF).’ The study aims to evaluate the safety and efficacy of using allogenic bone marrow-derived mesenchymal stem cells to treat ischemic heart failure with reduced ejection fraction, a condition characterized by the heart’s inability to pump blood efficiently. This research is significant as it explores a novel therapeutic approach for a condition with limited treatment options.
BioCardia, Inc. has announced that its 2025 Annual Meeting of Stockholders will take place on December 2, 2025, at 9:00 a.m. Pacific Time in Palo Alto, California. The company has set October 8, 2025, as the record date for stockholders eligible to vote and October 17, 2025, as the deadline for stockholder proposals and nominations for the meeting, in compliance with SEC regulations.
The most recent analyst rating on (BCDA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
On October 2, 2025, BioCardia, Inc. announced it has regained compliance with Nasdaq’s Listing Rule 5550(b)(1), ensuring its continued listing on the Nasdaq Stock Market. This achievement follows BioCardia’s efforts to strengthen its financial position by raising capital to support the development of its therapeutic candidates and advance its approved products.
The most recent analyst rating on (BCDA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
On September 22, 2025, BioCardia announced a positive preliminary clinical consultation with Japan’s PMDA regarding the CardiAMP Heart Failure Trial results. This meeting was a preparatory step for a formal consultation on the clinical data’s acceptability for approval submission. The PMDA requested additional information on various aspects of the trial, and BioCardia plans to address these queries before a formal consultation later in the year. This development could potentially enhance BioCardia’s position in the market by enabling access for patients with significant therapeutic needs.
The most recent analyst rating on (BCDA) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
On September 19, 2025, BioCardia, Inc. completed a significant financial transaction by selling 4,800,000 shares of common stock and accompanying warrants, raising approximately $5.1 million in net proceeds. This strategic move, involving key company directors and executive officers, is expected to bolster the company’s financial position and potentially impact its market operations by restricting certain stock issuance activities until March 2026.
The most recent analyst rating on (BCDA) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
On September 18, 2025, BioCardia announced the pricing of a public offering of 4,800,000 shares of common stock and short-term warrants, expected to raise $6 million upfront with potential additional proceeds of $6 million if warrants are fully exercised. The proceeds are intended for working capital and advancing biotherapeutic candidates, with H.C. Wainwright & Co. acting as the exclusive placement agent.
The most recent analyst rating on (BCDA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
On September 18, 2025, BioCardia announced promising results from the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial. The trial’s open label roll-in cohort showed that the therapy was well tolerated and led to significant improvements in exercise tolerance and a reduction in angina episodes at the six-month mark. These results suggest that CardiAMP Cell Therapy could address the unmet needs of patients with chronic myocardial ischemia and refractory angina, potentially enhancing BioCardia’s position in the cardiovascular therapeutics market.
The most recent analyst rating on (BCDA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
The recent earnings call for BioCardia painted a picture of cautious optimism. The company is making significant strides in clinical trials and regulatory pathways, particularly in Japan, with promising partnership discussions on the horizon. However, challenges remain with increased R&D expenses, a rise in net loss, and low cash reserves. The sentiment expressed during the call was one of cautious optimism, with a strong focus on achieving regulatory approvals and forming strategic partnerships to drive future growth.
On August 13, 2025, BioCardia, Inc. and CART-Tech, B.V. announced an exclusive development and commercialization agreement for Heart3D™ Fusion Imaging, aimed at enhancing cardiac biotherapeutic delivery and biopsy procedures. The system, which fuses two-dimensional x-ray images with three-dimensional anatomical heart models, is initially intended for research use and may later be approved for standard clinical practice. This partnership leverages both companies’ expertise and intellectual property, with BioCardia securing exclusive distribution rights for biotherapeutic delivery worldwide and cardiac biopsy in the U.S. The collaboration is expected to improve procedural planning and real-time image precision, potentially generating significant revenue if adopted as a standard of care.
The most recent analyst rating on (BCDA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.